200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score

Background

Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-stage Hepatocellular carcinoma (HCC) patients. However, predicting the Survival of hepatocellular carcinoma (HCC) patients receiving TACE remains challenging.

Methods

This retrospective study included 1805 HCC patients receiving TACE. Each patient was randomized to a training set (n = 1264) and a validation set (n = 541). We investigated prognostic factors in the training set and developed an easily applicable ALFP (ALBI grade, AFP, and Prothrombin time) score, which was evaluated in the validation set.

Results

We built the ALFP score using baseline ALBI grade 2 or 3 (HR 1.301, 95% CI 1.073-1.577，p = 0.007) and AFP ≥ 100 ng/ml （HR 1.328, 95% CI 1.133-1.557, p < 0.001）and PT 13.1 s （HR 1.262, 95% CI 1.047-1.521, p=0.015）, which were identified as unfavorable prognosis factors in a multivariate analysis. The median OS in patients with ALFP scores of 0, 1, 2, and 3 points was 50.1 months (95% CI NA), 33.6months (95% CI 27.4–39.8), and 20.4months (95% CI 18.0–22.8)， and 12.7 months (95% CI 10.2–15.2), respectively; the difference was statistically significant (p < 0.001).the result were confirmed in the validation set(The median OS ,0/1/2/3 points = 42.5/32.6/20.4 /13.0 months, p < 0.0019).

Conclusions

The ALFP score can predict the prognosis of HCC patients receiving TACE.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Xiong Chen.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.